Literature DB >> 20680638

Posterior fossa metastasis in lung cancer patients with vertigo.

Shunji Hiyashi1, Po-Wen Cheng, Yi-Ho Young.   

Abstract

This study investigated whether vertiginous attacks indicate a high probability for posterior fossa metastasis in lung cancer patients. Twenty-five lung cancer patients having vertiginous episodes were enrolled in this study. All patients underwent a battery of audiovestibular function testing and MR imaging study. Ten (40%) of 25 lung cancer patients with vertigo were proven to have posterior fossa metastasis (PM1 group), while the other 15 patients had no posterior fossa metastasis (PM0 group). Of the PM1 group, all were adenocarcinoma with the women predominant (80%). Seven (70%) and two (13%) patients of PM1 and PM0 groups had other (bone, liver) systemic metastases before the vertigo episodes, respectively, exhibiting significant difference between them. However, no statistical differences existed in the audiovestibular function testing between the two groups. In contrast with 58% of PM0 group, none of the patients in PM1 group survived for > 3 years after the vertiginous attacks. The mean interval from vertiginous episode to death was 16 months (range 5-27). In conclusion, vertiginous attack in a lung cancer patient having other systemic metastases indicates a high probability of posterior fossa metastasis.

Entities:  

Mesh:

Year:  2010        PMID: 20680638     DOI: 10.1007/s00405-010-1351-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  18 in total

1.  Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma.

Authors:  T J Robnett; M Machtay; J P Stevenson; K M Algazy; S M Hahn
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

2.  Metastases to temporal bones from primary nonsystemic malignant neoplasms.

Authors:  T I Gloria-Cruz; P A Schachern; M M Paparella; G L Adams; S E Fulton
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2000-02

3.  Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?

Authors:  F Andre; D Grunenwald; J L Pujol; P Girard; A Dujon; L Brouchet; P Y Brichon; V Westeel; T Le Chevalier
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

4.  Differentiation between cerebellopontine angle tumors in cancer patients.

Authors:  Tsung-Wei Huang; Yi-Ho Young
Journal:  Otol Neurotol       Date:  2002-11       Impact factor: 2.311

5.  High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation.

Authors:  Harvey J Mamon; Beow Yong Yeap; Pasi A Jänne; Jason Reblando; Sarah Shrager; Michael T Jaklitsch; Steven Mentzer; Jeanne M Lukanich; David J Sugarbaker; Elizabeth H Baldini; Stuart Berman; Arthur Skarin; Raphael Bueno
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

6.  Solitary metastasis of lung cancer to the cerebellopontine angle--case report.

Authors:  M Minami; J Hanakita; H Suwa; H Suzui; K Fujita; T Nakamura
Journal:  Neurol Med Chir (Tokyo)       Date:  1996-03       Impact factor: 1.742

7.  Metastatic lung cancer in the cerebellopontine angles mimicking bilateral acoustic neuroma.

Authors:  Subramanian Hariharan; Jianhua Zhu; Mangala A Nadkarni; John E Donahue
Journal:  J Clin Neurosci       Date:  2005-02       Impact factor: 1.961

8.  Metastatic adenocarcinoma of the temporal bone.

Authors:  B A Hill; R I Kohut
Journal:  Arch Otolaryngol       Date:  1976-09

9.  Metastatic lesions involving the cerebellopontine angle.

Authors:  W T Yuh; N A Mayr-Yuh; T M Koci; J H Simon; K L Nelson; J Zyroff; J R Jinkins
Journal:  AJNR Am J Neuroradiol       Date:  1993 Jan-Feb       Impact factor: 3.825

10.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.

Authors:  W R Wasserstrom; J P Glass; J B Posner
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.